Viimeisin päivitys :
08/05/2024
Syöpälääke   Dactinomycin  
Injektioneste
Stabilius liuoksessa Stabilius seoksissa Tekijät, jotka vaikuttavat stabiliuteen Yhteensopivuus Antotapa Viitteet Pdf
   Kemiallinen rakenne  

Kauppanimi   Kauppanimi     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Cosmegen Argentiina, Australia, Iran, Italia, Itävalta, Kanada, Kreikka, Malesia, Meksiko, New Zealand, Norja, Ranska, Ruotsi, Suomi, Sveitsi, Yhdysvallat
Cosmegen Lyovac Irlanti, Iso-Britannia, Romania
Dacilon Chile, Intia, Marokko
Dacmozen Intia
Dactino Intia
Dactinomicina Chile, Ecuador, Kolumbia, Marokko
Dactinomycin New Zealand
Lyovac Cosmegen Belgia, Hollanti, Luxemburg, Saksa
Viitteet   Injektioneste   Viitteet : Dactinomycin  
Tyyppi Julkaisu
3 Lehti Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
84 Lehti Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
99 Lehti Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169 Lehti Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363.
182 Lehti Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60.
244 Lehti Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
249 Lehti Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
307 Lehti Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
334 Lehti Trissel LA, Tramonte SM, Grilley BJ.
Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 988-992.
335 Lehti Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406.
492 Lehti Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189.
729 Lehti Rusmin S, Welton S, DeLuca P, DeLuca PP.
Effect of inline filtration on the potency of drugs administered intravenously.
Am J Hosp Pharm 1977 ; 34: 1071-1074.
857 Lehti Kanke M, Eubanks JL, DeLuca PP.
Binding of selected drugs to a “treated” inline filter.
Am J Hosp Pharm 1983 ; 40: 1323-1328.
905 Lehti Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
1178 Lehti Benvenuto JA, Anderson RW, Kerkof K, Smith RG, Loo TL.
Stability and compatibility of antitumor agents in glass and plastic containers.
Am J Hosp Pharm 1981 ; 38: 1914-1918.
1322 Lehti Ennis CE, Merritt RJ, Neff DN.
In vitro study of inline filtration of medications commonly administered to pediatric cancer patients.
JPEN 1983 ; 7: 156-158.
1410 Lehti Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1423 Lehti Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
4153 Laboratorio Dactinomycin (Cosmegen Lyovac®) - Summary of Product Characteristics
Orphan Europe (UF) Limited 2014

  Mentions Légales